1. Silencing the FABP3 gene in insulin-secreting cells reduces fatty acid uptake and protects against lipotoxicity.
- Author
-
Hyder A, Sheta B, Eissa M, and Schrezenmeir J
- Subjects
- Animals, Apoptosis, Lipid Metabolism genetics, Insulin metabolism, Mice, Rats, Humans, Insulin Secretion genetics, Fatty Acid-Binding Proteins metabolism, Fatty Acid-Binding Proteins genetics, Insulin-Secreting Cells metabolism, Fatty Acid Binding Protein 3 metabolism, Fatty Acid Binding Protein 3 genetics, Gene Silencing, Fatty Acids metabolism
- Abstract
Background: Long-term exposure of pancreatic islets to fatty acids (FAs), common in obesity, metabolic syndrome, and type 2 diabetes, leads to a compensatory hyperactivity followed by inflammation, apoptosis, dysfunctional beta cells, and results in insulin dependence of the patient. Restriction of fatty uptake by islet beta cells may protect them from lipotoxicity., Purpose: Pancreatic islet beta cells express the fatty acid binding protein 3 (FABP3) to bind FAs and to orchestrate lipid signals. Based on this, we investigated whether downregulation of FABP3, by Fabp3 silencing, might slow lipid metabolism and protect against lipotoxicity in insulin-secreting cells., Results: Neither Fabp3 silencing, nor overexpression affected the glucose-stimulated insulin secretion in absence of FAs. Fabp3 silencing decreased FA-uptake, lipid droplets formation, and the expression of the lipid accumulation-regulating gene Dgat1 in Ins1E cells. It reduced FA-induced inflammation by deactivation of NF-κB, which was associated with upregulation of IκBα and deactivation of the NF-κB p65 nuclear translocation, and the downregulation of the cytokines ILl-6, IL-1β, and TNFα. Ins1E cells were protected from the FA-induced apoptosis as assessed by different parameters including DNA degradation and cleaved caspase-3 immunoblotting. Furthermore, FABP3 silencing improved the viability, Pdx1 gene expression, and the insulin-secreting function in cells long-term cultured with palmitic acid. All results were confirmed by the opposite action rendered by FABP3 overexpression., Conclusion: The present data reveals that pancreatic beta cells can be protected from lipotoxicity by inhibition of FA-uptake, intracellular utilization and accumulation. FABP3 inhibition, hence, may be a useful pharmaceutical approach in obesity, metabolic syndrome, and type 2 diabetes., Competing Interests: Declarations. Conflict of interest: The authors declare that they have no conflict of interest. Ethical standard: For animal experiments, the “Principles of laboratory animal care” (NIH publication No. 86-23, revised 1985) were followed, and the study was approved by the institutional review board of Damietta University. Informed consent: For this animal study, informed consent is not required., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF